廣告
香港股市 已收市

  • 恒指

    16,224.14
    -161.73 (-0.99%)
     

  • 國指

    5,746.61
    -57.25 (-0.99%)
     

  • 上證綜指

    3,065.26
    -8.96 (-0.29%)
     

  • 滬深300

    3,541.66
    -28.14 (-0.79%)
     

  • 美元

    7.8319
    +0.0007 (+0.01%)
     

  • 人民幣

    0.9239
    +0.0002 (+0.02%)
     

  • 道指

    37,986.40
    +211.02 (+0.56%)
     

  • 標普 500

    4,967.23
    -43.89 (-0.88%)
     

  • 納指

    15,282.01
    -319.49 (-2.05%)
     

  • 日圓

    0.0504
    +0.0000 (+0.02%)
     

  • 歐元

    8.3453
    +0.0109 (+0.13%)
     

  • 英鎊

    9.6890
    -0.0500 (-0.51%)
     

  • 紐約期油

    83.24
    +0.51 (+0.62%)
     

  • 金價

    2,406.70
    +8.70 (+0.36%)
     

  • Bitcoin

    63,871.13
    +2,449.45 (+3.99%)
     

  • CMC Crypto 200

    1,371.97
    +59.34 (+4.52%)
     

Sarepta Reports One Heart Inflammation Case In Duchenne Gene Therapy Trial

Vandana Singh
·1 分鐘文章

  • Sarepta Therapeutics Inc (NASDAQ: SRPT) shared new functional data across multiple studies from the SRP-9001 (delandistrogene moxeparvovec) program for Duchenne muscular dystrophy.

  • SRP-9001 is an investigational gene therapy under development in partnership with Roche Holdings AG (OTC: RHHBY).

  • Results from Cohort 1 demonstrated a 3.8-point improvement and 3.2-point improvement on the Duchenne functional scale 52 weeks after treatment compared to a propensity-score weighted external control.

  • Related: Sarepta Therapeutics' Shares Plummet Following FDA's Clinical Hold On MOMENTUM Study.

  • Additionally, across multiple new analyses, SRP-9001 treated patients showed statistically significant and clinically meaningful benefits versus propensity-matched external controls.

  • After four years, SRP-9001-treated participants had a positive mean 7.0-point difference on the Duchenne functional scale compared to baseline.

  • The safety and tolerability profile of SRP-9001 is similar to past reports. The most common treatment-related adverse event was vomiting. Increases in liver enzymes were transient and responsive to steroids.

  • In Study 9001-103, there was one new serious adverse event of myocarditis in Cohort 2, resolved after one month.

  • Price Action: SRPT shares are down 1.98% at $74.24 during the market session on the last check Wednesday.

See more from Benzinga

廣告

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.